UBS Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.72B | Buy |
4,043,568
+479,648
| +13% | +$486M | 0.56% | 16 |
|
|
2025
Q4 | $3.83B | Sell |
3,563,920
-406,325
| -10% | -$389M | 0.62% | 14 |
|
|
2025
Q3 | $3.03B | Buy |
3,970,245
+50,838
| +1% | +$37.8M | 0.47% | 20 |
|
|
2025
Q2 | $3.06B | Buy |
3,919,407
+80,555
| +2% | +$62.6M | 0.53% | 16 |
|
|
2025
Q1 | $3.17B | Buy |
3,838,852
+437,713
| +13% | +$364M | 0.58% | 15 |
|
|
2024
Q4 | $2.63B | Sell |
3,401,139
-194,780
| -5% | -$161M | 0.49% | 16 |
|
|
2024
Q3 | $3.19B | Buy |
3,595,919
+633,098
| +21% | +$569M | 0.69% | 17 |
|
|
2024
Q2 | $2.68B | Buy |
2,962,821
+273,596
| +10% | +$219M | 0.66% | 17 |
|
|
2024
Q1 | $2.09B | Buy |
2,689,225
+145,246
| +6% | +$103M | 0.52% | 20 |
|
|
2023
Q4 | $1.48B | Buy |
2,543,979
+320,958
| +14% | +$187M | 0.44% | 32 |
|
|
2023
Q3 | $1.19B | Sell |
2,223,021
-217,432
| -9% | -$112M | 0.41% | 40 |
|
|
2023
Q2 | $1.14B | Buy |
2,440,453
+109,536
| +5% | +$45.9M | 0.39% | 44 |
|
|
2023
Q1 | $800M | Buy |
2,330,917
+423,025
| +22% | +$143M | 0.29% | 66 |
|
|
2022
Q4 | $698M | Buy |
1,907,892
+855,819
| +81% | +$303M | 0.26% | 74 |
|
|
2022
Q3 | $340M | Sell |
1,052,073
-134,813
| -11% | -$42.7M | 0.15% | 136 |
|
|
2022
Q2 | $385M | Sell |
1,186,886
-34,135
| -3% | -$10.2M | 0.16% | 133 |
|
|
2022
Q1 | $350M | Sell |
1,221,021
-218,932
| -15% | -$56.3M | 0.12% | 184 |
|
|
2021
Q4 | $398M | Buy |
1,439,953
+15,929
| +1% | +$4.04M | 0.11% | 176 |
|
|
2021
Q3 | $329M | Buy |
1,424,024
+88,136
| +7% | +$21.8M | 0.1% | 197 |
|
|
2021
Q2 | $307M | Buy |
1,335,888
+205,800
| +18% | +$41.3M | 0.1% | 204 |
|
|
2021
Q1 | $211M | Sell |
1,130,088
-267,360
| -19% | -$52.3M | 0.07% | 281 |
|
|
2020
Q4 | $236M | Buy |
1,397,448
+345,099
| +33% | +$51.5M | 0.08% | 251 |
|
|
2020
Q3 | $156M | Sell |
1,052,349
-45,031
| -4% | -$6.97M | 0.06% | 289 |
|
|
2020
Q2 | $180M | Sell |
1,097,380
-83,396
| -7% | -$12.8M | 0.08% | 256 |
|
|
2020
Q1 | $164M | Sell |
1,180,776
-418,822
| -26% | -$57.5M | 0.08% | 241 |
|
|
2019
Q4 | $210M | Buy |
1,599,598
+301,855
| +23% | +$35M | 0.07% | 257 |
|
|
2019
Q3 | $145M | Buy |
1,297,743
+84,767
| +7% | +$9.44M | 0.06% | 307 |
|
|
2019
Q2 | $134M | Sell |
1,212,976
-106,700
| -8% | -$12.6M | 0.05% | 317 |
|
|
2019
Q1 | $171M | Buy |
1,319,676
+153,997
| +13% | +$18.7M | 0.07% | 250 |
|
|
2018
Q4 | $135M | Sell |
1,165,679
-135,676
| -10% | -$15.2M | 0.06% | 292 |
|
|
2018
Q3 | $140M | Sell |
1,301,355
-6,294
| -0.5% | -$629K | 0.06% | 311 |
|
|
2018
Q2 | $112M | Sell |
1,307,649
-180,489
| -12% | -$14.8M | 0.05% | 371 |
|
|
2018
Q1 | $115M | Sell |
1,488,138
-31,772
| -2% | -$2.56M | 0.05% | 347 |
|
|
2017
Q4 | $128M | Buy |
1,519,910
+320,444
| +27% | +$27.3M | 0.05% | 345 |
|
|
2017
Q3 | $103M | Sell |
1,199,466
-245,097
| -17% | -$20.1M | 0.05% | 371 |
|
|
2017
Q2 | $119M | Buy |
1,444,563
+175,275
| +14% | +$14.3M | 0.06% | 320 |
|
|
2017
Q1 | $107M | Sell |
1,269,288
-1,034,446
| -45% | -$82.9M | 0.06% | 320 |
|
|
2016
Q4 | $169M | Buy |
2,303,734
+358,703
| +18% | +$26.7M | 0.09% | 235 |
|
|
2016
Q3 | $156M | Sell |
1,945,031
-411,185
| -17% | -$32.9M | 0.09% | 233 |
|
|
2016
Q2 | $186M | Sell |
2,356,216
-239,423
| -9% | -$18M | 0.12% | 190 |
|
|
2016
Q1 | $187M | Buy |
2,595,639
+1,367,335
| +111% | +$103M | 0.13% | 180 |
|
|
2015
Q4 | $103M | Buy |
1,228,304
+398,968
| +48% | +$33.1M | 0.07% | 288 |
|
|
2015
Q3 | $69.4M | Buy |
829,336
+179,590
| +28% | +$15.2M | 0.05% | 371 |
|
|
2015
Q2 | $54.2M | Sell |
649,746
-267,459
| -29% | -$20.4M | 0.04% | 491 |
|
|
2015
Q1 | $66.6M | Sell |
917,205
-38,590
| -4% | -$2.75M | 0.05% | 421 |
|
|
2014
Q4 | $65.9M | Buy |
+955,795
| New | +$64.5M | 0.05% | 431 |
|
Other funds holding LLY
VCM
VPM
UBS Group's LLY Position: Q1 2026 in Review
UBS Group increased its Eli Lilly (LLY) stake by 13% in Q1 2026, buying an estimated $486M and bringing the position to 4,043,568 shares worth $3.72B. The position accounts for 0.56% of the portfolio, ranked #16.
UBS Group first reported a position in LLY in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.83B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- UBS Group held 4,043,568 shares of Eli Lilly worth $3.72B as of Q1 2026.
- UBS Group bought 479,648 Eli Lilly shares in Q1 2026, an estimated $486M.
- Eli Lilly made up 0.56% of UBS Group's portfolio in Q1 2026, its #16 holding.
- UBS Group first reported a position in Eli Lilly in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Eli Lilly position peaked at $3.83B in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.